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Abstract
Background: To investigate dynamic fluctuations of serum viral load and peripheral T-lymphocyte
subpopulations of chronic hepatitis B patients and their correlation during entecavir therapy.
Methods: Fifty-five patients received entecavir 0.5 mg/d therapy. Serum HBV DNA load was
measured by Real-Time-PCR, and the levels of peripheral T-lymphocyte subpopulations by flow
cytometry biweekly, every four weeks and every eight weeks during weeks 1–12, 13–24 and 24–
48, respectively. Multilevel modelling was used to analyse the relationship between these variables.
Results: Of the 55 patients, all HBeAg positive and with detectable HBV DNA, the majority
(81.8%) had serum levels of HBV DNA over 107 copies per milliliter. HBV viral load dropped
sharply during the first two weeks. In 28 and 43 patients, the level became undetectable from week
24 and 48, respectively. Using pre-therapy level as the reference, a significant decrease in CD8+ T
cells and increase in CD4+ T cells were found from week 12. Both parameters and CD4+/CD8+
ratio steadily improved throughout the 48 weeks. Multilevel analyses showed that the level of
decrement of HBV DNA was associated with the increment of T-lymphocyte activities only in the
later period (4–48 week). After 4 weeks of therapy, for each log10 scale decrement of HBV DNA,
the percentage of CD4+ lymphocyte was increased by 0.49 and that of CD8+ decreased by 0.51.
Conclusion: T-lymphocyte subpopulations could be restored partially by entecavir treatment in
patients with chronic hepatitis B concurrently with reduction of viremia.
Background
Hepatitis B virus (HBV) infection remains an important
health problem with more than 350 million chronically
infected people worldwide, and approximately 1 million
people die annually from HBV-related disease, such as
liver failure, cirrhosis and hepatocellular carcinoma [1].
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Infection with HBV in adults usually results in a self-lim-
iting, acute hepatitis, which confers protective immunity
and causes no further disease. In patients with an acute
self-limiting HBV infection, specific CD4+ and CD8+ T cell
responses are important for control of the infection [2].
Patients with a chronic HBV infection lack such vigorous,
polyclonal, and multispecific T cell responses, but instead
exhibit a weak, narrowly focused, or undetectable virus-
specific T cell response [2-5]. The reasons for this lack of
responsiveness and the mechanisms that contribute to the
failure of the virus-specific T cell response in chronically
infected patients are not understood [3-8]. Potential
mechanisms include T-cell exhaustion, depletion, anergy,
ignorance and T cell dysfunction and epitope mutation
[6,7].
Most previous studies suggested that T cell failure is asso-
ciated with a persistent high viral replication [9,10]. An
efficient antiviral T cell response can be restored tran-
siently by lamivudine treatment in patients with chronic
hepatitis B (CHB) concurrently with reduction of viremia.
This indicates the importance of viral load in the patho-
genesis of T cell hyporesponsiveness in these patients [11-
13]. However, the relationship between HBV specific T-
cell response and HBV viral load in persistent infection is
complicated by their close correlation and remains
unclear [6,7]. Furthermore, correlation of T-cell failure
with viral replication is likely to be a crucial step in the
treatment of chronic hepatitis B [6,7]. Therefore, under-
standing of the immune response upon HBV infection
and the mechanisms responsible for T-cell failure may
help identify rational therapeutic strategies to restore T-
cell failure, thus allowing successful stimulation of antivi-
ral T cell responses for obtaining long-lasting viral sup-
pression and disease remission. This may also offer us a
possibility to better individualize HBV treatment based on
the patient's immune condition and viral profile.
Two major types of antiviral drugs are being used for the
treatment of chronic HBV: drugs that directly interfere
with virus replication and drugs that modulate the HBV-
specific immune response. Nucleoside and nucleotide
analogues, such as lamivudine, adefovir and entecavir,
directly inhibit reverse transcriptase and thereby impair
viral replication. Interferon (IFN) has marked immu-
nomodulatory, but less pronounced direct antiviral,
effects. Recently, novel antiviral agents have been evalu-
ated for their therapeutic potential for treatment of
chronic hepatitis B [14-18]. Entecavir, one of the most
promising of such agents, is a guanosine analogue and a
potent inhibitor of the HBV polymerase. Recent studies
suggested that over a 12-month treatment period the anti-
viral efficacy of entecavir would be superior to that of lam-
ivudine [19-22]. It inhibits HBV DNA replication at three
stages: priming of HBV DNA polymerase, a step involving
the covalent linkage with guanosine triphosphate; the
reverse transcription of the negative strand HBV DNA
from the pregenomic messenger RNA; and the synthesis of
the positive strand HBV DNA. The potency of entecavir for
inhibiting HBV replication provides a possible avenue for
documenting possible correlation between high viral load
and T cell failure. It is important to know whether reduc-
tion of viral load resulting from antiviral treatment can
cause a recovery of the impaired T cell response in CHB
patients. The aim of this study was to analyze the dynam-
ics of the peripheral T-lymphocyte subpopulations profile
and viral load in HBeAg positive CHB patients during the
first year antiviral therapy with entecavir.
Methods
Enrollment of study subjects
Fifty-five consecutive CHB patients (42 males and 13
females, age 16 to 60 years) who were recruited from the
First Affiliated Hospital of Kunming Medical University,
the Third Municipal People's Hospital of Kunming and
the Yunnan General Hospital of The Chinese People's
Armed Police Forces, between January 2006 and February
2007, were prospectively included into the study. All
patients had presence of hepatitis B surface antigen
(HBsAg) and HBeAg in the serum for at least 12 months;
positive serum tests for HBV DNA with high viral load
more than 105 copies/mL, documented on at least two
occasions, at least 3 months apart, during the 12 months
before entry; aminotransferase levels higher than 2 times
the upper normal limit for at least 12 months; and liver
biopsy taken within 12 months before enrollment show-
ing chronic hepatitis [23]. Patients treated with immuno-
suppressive or antiviral therapy within 1 year before entry,
and those with concurrent hepatitis C virus, hepatitis
delta virus, human immunodeficiency virus infections,
liver cirrhosis, causes of liver disease other than HBV,
intravenous drug abuse, pregnancy, malignancy, chronic
renal failure, or other serious medical illness that might
interfere with this trial, were excluded. Informed consent
was obtained from each study patient. The study protocol
conformed to the guidelines of Declaration of Helsinki
and was approved by ethics committees of the Faculty of
Medicine of Prince of Songkla University and the First
Affiliated Hospital of Kunming Medical University.
Study design
This design used was single cohort with intervention
study. The patients received entecavir at a daily dose of 0.5
mg for 48 weeks. Clinical, virological, biochemical and
immunological parameters were assessed at baseline, then
biweekly, every four weeks and every eight weeks during
weeks 1–12, 13–24 and 24–48, respectively.
Serological liver function tests and hepatitis B virus 
markers evaluation
Biochemical investigations including serum alanine ami-
notransferase (ALT), aspartate transaminase (AST) andBMC Infectious Diseases 2008, 8:123 http://www.biomedcentral.com/1471-2334/8/123
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total bilirubin (TBiL) were tested with routine automated
techniques (upper limit of nomal; 40 U/L, 40 U/L and
17.1  μmol/mL, respectively) (AU2700, Japan). HBV
markers (HBsAg, HBsAb, HBeAg, HBeAb, HBcAb, Anti-
HBcAb IgM) were measured at a virological laboratory
with the use of ELISA (enzyme-linked immunosorbent
assay) method (Anthos 2010, Austria). The experimental
methods followed the guideline written in the reagent kit
(Sino-American Biotech Co., Ltd).
Quantitative detection of HBV DNA
Serum HBV DNA load was assessed with real-time fluores-
cent quantitative polymerase chain reaction method
(Real-Time-PCR) using a Lightcycler PCR system (FQD-
33A, Bioer) with a lowest limit of detection of approxi-
mately 1000 viral genome copies/mL. The handling pro-
cedures were performed in strict accordance with the
reagent kit (Shenzheng PG Biotech Co., Ltd.) package
insert. The primer was provided in the kit, the reaction
volume was 40 μL, and the reaction condition was 37°C
for 5 min, 94°C for 1 min then 40 cycles as 95°C for 5 sec
and 60°C for 30 sec.
Peripheral blood T-lymphocyte subsets measurement
The blood samples were analysed with a Multi-Q-Prep
processor (Coulter, USA) and thereafter with Epics-XL
flow cytometry (FCM) (Coulter, USA). Lymphocytes were
analysed using a gate set on forward scatter versus side
scatter, and a three-color flow cytometry to combination
reagent of CD3, CD4, CD8. Anti-human monoclonal
antibodies CD3-PE-CY5/CD4-FITC/CD8-PE were from
Immunotech, Ltd, USA. For each sample, the detection
was analyzed with the CELLQuest software (Coulter,
USA). The results were expressed as the percentages of
CD3+, CD4+ and CD8+ T-cells found to be positive for the
marker antigen in the total T cell population.
Statistical analysis
Descriptive statistics were used to examine the age, sex,
serum level of HBV viral load, T-lymphocyte subpopula-
tion, HBeAg status, ALT, AST and total bilirubin. Contin-
uous data were presented as means ± standard deviations
and were compared by a two-tailed Student t test or one-
way ANOVA adjusted for multiple comparision, as appro-
priate. Categorical data were compared by a two-tailed
chi-square test or Fisher's exact test. The aim in longitudi-
nal analysis was to investigate the effects of covariates
both on the overall level of the responses and on changes
of the responses over time. Thus, multilevel regression
with random effects among subjects was employed to
assess the independent effects of variables on peripheral
blood T-lymphocytes. The changes of peripheral blood T-
lymphocyte subpopulations during treatment are depend-
ent variables of the first level nested within the subject
which is at the second level. On the other hand, the effects
of age, sex, treatment time (week) and the changes of viral
load and HBeAg expression were treated as fixed effects
common to all subjects. Variables yielding a P value of ≤
0.2 in the univariate analysis were included in the multi-
variate analysis, and the model refined by backward elim-
ination guided by the change in log likelihood of
successive models. A final P value of less than 0.05 was
considered statistically significant. Computations were
carried out with the aid of R softwere version 2.6.0, and
glmmPQL function [24]. The longitudinal plots were
done with Epicalc package version 2.6.0.2 [25].
Results
Demographic characteristics and clinical features of CHB 
patients
Fifty-five consecutive patients were enrolled in this study.
Characteristics of the patients are summarized in Table 1.
The sample is predominated by male, full grown adults
with a long period of HBV infection. The majority
(81.8%) had serum levels of HBV DNA over 107 copies
per milliliter. Most patients (73%, 40/55) were moderate
chronic hepatitis with moderate activity and mild or mod-
erate fibrosis (grade 3, stage 1–3; using the Scheuer grad-
ing and staging system) and 15% (8/55) patients were
severe chronic hepatitis with marked activity and marked
fibrosis and developing cirrhosis (grade 4, stage 2–4). No
patients were with previous hepatic decompensation. No
patient dropped out, and all completed the 48-week
therapy.
Changes in virological and enzyme parameters during the 
therapy
HBV DNA levels declined sharply by around 3 log10 cop-
ies/mL during the first two weeks, with a highly signifi-
cant reduction (p < 0.0001) at week 2 and thereafter, as
compared to those at baseline (Table 2 and Fig. 1); 31%,
51% and 78% of the patients had undetectable serum
HBV DNA levels at week 12, 24 and 48 respectively. The
magnitude of HBV DNA reduction was up to 63% of the
baseline level at the end of the study. The mean reduc-
tion in the serum HBV DNA levels at week 48 was 5 log10
copies per milliliter. At the end of week 24 and 48, the
proportion of subjects losing HBeAg and converting to
HBeAb positive were 6/55 (11%) and 9/55 (16%), and
4/55 (7.3%) and 9/55 (14.5%), respectively. Highly sig-
nificantly decreasing serum aminotransferase and total
bilirubin (ALT, AST and TBil) (p < 0.0001) occurred dur-
ing the first 2 weeks of the study (Table 2 and Fig. 1). At
week 48, ALT levels were normalized in 84% of the
patients. At the end of 24th and 48th weeks, complete
response (ALT normalization and HBV DNA and HBeAg
loss) was observed in 11% and 15%, respectively. There
was no evidence of drug resistance or adverse effect in
CHB patients treated for up to 48 weeks.BMC Infectious Diseases 2008, 8:123 http://www.biomedcentral.com/1471-2334/8/123
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Peripheral blood T-lymphocyte subpopulations changes
The effect of the entecavir therapy on alterations of the T
cell subpopulations are shown in Table 2 and Figure 1.
While the clearance of HBV DNA was relatively rapid,
improvement of T-lymphocyte subpopulations was grad-
ual but steady throughout the 48-week period. Only when
viremia viral load level dropped to approximately 4 log10
copies/mL, at weeks 12–16, could significant increases in
the CD3+ cells and in the CD4+/CD8+ ratio be observed (p
< 0.05, p < 0.01, respectively). All T-lymphocyte parame-
ters continued to improve and achieved highly significant
difference from the baseline (p < 0.0001) by the 48th
week. The increase in the CD4+/CD8+ ratio was a com-
bined result of an increase in the number of CD4+ cells
and a decrease in CD8+ cells. The magnitude of increase in
CD3+, CD4+ cells and CD4+/CD8+ ratio and decrease in
CD8+ cells was, respectively, 21.6%, 30.2%, 77.2% and
27.6% of pre-therapy levels at the end of study.
Multilevel regression predicting peripheral blood T-
lymphocyte subpopulations from relevant parameters
In Table 3, multilevel regression models using multivari-
ate random coefficient analysis among subjects are sepa-
rately summarized for CD3+, CD4+ and CD8+ cells, which
are the dependent variables, respectively. The fixed effects
part consists of coefficient (β) and standard error (SE) of
the effect of each predicting variable which act equally to
all subjects, while the random effects reflect variation of
the baseline level outcome variable among the subjects.
Interaction terms between log HBV DNA and period are
significant for all T-lymphocyte parameters, indicating
that effect of HBV DNA on these parameters after the first
2 week of therapy was significantly different from that in
the initial period. The main effect of HBV DNA was not
significant indicating no relationship during the initial
period. The signs of the interaction term were negative for
CD3+ and CD4+, and positive for CD8+ indicating that in
the later period, the level of decrement of HBV DNA was
associated with the increment of T-lymphocyte activities.
These effects have already been adjusted for time or
"week" as a continuous variable in the models. After 4
weeks of therapy, for each log10 scale decrement of HBV
DNA, the percentage of CD4+ lymphocyte was increased
by 0.49 and that of CD8+ decreased by 0.51. The relation-
ship before week 4 was not statistically significant.
Discussion
This study demonstrated that entecavir results in an early
rapid viral load reduction and continued virologic and
biochemical improvement and HBeAg seroconversion
through 48 weeks of treatment in CHB patients. Also a
decreased viral load in serum (an inhibition of virus rep-
lication) during antiviral treatment was accompanied by a
delayed restoration of peripheral T cell subpopulations.
Although the relationship was not significant during the
initial period (≤ 2 week), the level of decrement of HBV
DNA was associated with an increment of T-lymphocyte
activities in the later period (4–48 week). These responses
were sustained up to the end of the observation period.
Our data showed that entecavir treatment led to a rapid
drop of viremia in all patients and a slower HBeAg/HBeAb
seroconversion. Most patients experienced improvements
in serum ALT values after initiation of entecavir therapy.
The efficacy of entecavir appears to result from its potent
suppression of HBV replication, and this rapid viral sup-
pression occurred especially during the first two weeks.
The virologic and biochemical efficacy of entecavir con-
tinued through 48 weeks. The improvement of virologic
and biochemical parameters found in this study was in
Table 1: Characteristics of the CHB patients at entry to the study*
Characteristics All patients
(n = 55)
Sex (male/female) 42/13
Mean age (in years)† 30.9 ± 8.5
Duration of infection (years)† 13.8 ± 8.7
Serum ALT level (IU/L)† 251.4 ± 66.1
Serum AST level (IU/L)† 195.7 ± 81.6
Serum total bilirubin level (μmol/mL)† 26.7 ± 18.1
Serum HBV DNA (copies/mL)‡
> 1.0 × 105 ~ 1.0 × 107 10 (18.2)
> 1.0 × 107 45 (81.8)
HBV DNA (Log, copies/mL)† 7.9 ± 1.1
Diagnosis of chronic hepatitis (Histopathological results)‡
Mild (grade 1–2, stage 0–2) 7 (12.7)
Moderate (grade 3, stage 1–3) 40 (72.7)
Severe (grade 4, stage 2–4) 8 (14.5)
* CHB, chronic hepatitis B; ALT, alanine aminotransferase; AST, aspartate aminotransferase; Normal values: ALT, ≤40 IU/L; AST, ≤40 IU/L; total 
bilirubin, ≤17.1 μmol/mL. † Date are expressed as mean ± SD; ‡ Data are expressed as no. (%).BMC Infectious Diseases 2008, 8:123 http://www.biomedcentral.com/1471-2334/8/123
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agreement with recent studies of patients with chronic
hepatitis B [19-22]. Global phase III studies demonstrated
that after one year of treatment, entecavir is superior to
lamivudine [19-22] in its ability to reduce HBV DNA to
undetectable levels, normalize ALT, and improve liver his-
tology in nucleoside-naive HBeAg-positive and -negative
patients and lamivudine-retractory HBeAg-positive
patients. Direct comparison of entecavir and adefovir for
a duration of 24 wk showed a decline of HBV DNA of 6.97
log10 copies/mL for entecavir and 4.84 log10 copies/mL for
adefovir. PCR undetectability (HBV DNA < 300 copies/
mL) was reached in 45% of entecavir treated patients vs
13% of those receiving adefovir [26]. Significant differ-
ence in rapid viral load reduction between entecavir and
adefovir was as early as day 10 (-0.655, 95% CI: -1.30, -
0.01) [26]. A similar pattern was also observed between
entecavir and lamivudine [19-22]. The virologic and bio-
chemical efficacy of entecavir is maintained with pro-
longed treatment for up to 96 weeks [27].
To our knowledge, no data have been reported concerning
the synchronous effects of entecavir on the serial measure-
ment of peripheral blood lymphocyte subpopulations
and serum HBV DNA concentrations in patients with
chronic hepatitis B. During entecavir-therapy, we detected
a shift in the CD4+/CD8+  ratio, owing to a relative
decrease in the number of CD8+ cells and increase in the
number of CD4+ lymphocytes, and an increase in the
number of CD3+ cells, concomitantly with a quantitative
reduction in viral replication. The benefit of entecavir on
Dynamic fluctuations of serum levels of viral load and ALT and peripheral T-lymphocyte subpopulations during entecavir treat- ment over time Figure 1
Dynamic fluctuations of serum levels of viral load and ALT and peripheral T-lymphocyte subpopulations dur-
ing entecavir treatment over time. Note: The thick lines are the mean values.
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T cell profile was not immediately significant at the time
of rapid reduction of viral load during the first 2 weeks. T
cell subpopulations restoration had a tendency to increase
or accumulate gradually after initiation of treatment.
Although the relationship was not significant during the
initial period (≤ 2 week), the level of decrement of HBV
DNA was associated with the increment of T-lymphocyte
activities in the later period (4–48 week). Our results also
showed that the magnitude of restoration of these param-
eters was maintained up to the end of the study. The inde-
pendent effect of viral load on peripheral T-lymphocyte
subpopulations profile found in this study was partly in
accordance with previous studies. Stoop et al [28] and Lau
et al [29] reported that inhibition of viral replication
induced by adefovir therapy resulted in a increased HBV-
specific proliferation and IFN-γ production, and a tran-
sient increase in HBV-specific CD4+  T-cells, but no
increase in HBV-specific CD8+ T-cells. Kondo et al [30]
suggested that lamivudine therapy induced mainly cyto-
toxic T lymphocytes (CTLs) that were less frequent before
the therapy. Since recovered CTLs maintained the ability
to produce interferon-gamma in response to peptides,
Table 2: Response to treatment during entecavir therapy (n = 55) *
Response to treatment over time (weeks)
pre (baseline) 2nd 4th 12th 16th 24th 48th
HBVDNA-negation† 0 8 (14.5) 13 (23.6) 17 (30.9) 21 (38.2) 28 (50.9) 43 (78.2)g
HBeAg-negation† 0 0 0 3 (5.5) 3 (5.5) 6 (10.9) 9 (16.4)h
HBeAg/HBeAb seroconversion† 0 0 0 1 (1.8) 2 (3.6) 4 (7.3) 8 (14.5)
ALT normalization† 0 0 7 (12.7) 31 (56.4) 39(70.9) 47 (85.5) 46 (83.6)
ALT normal/HBeAg & HBVDNA-
negation†
0 0 0 3 (5.5) 3 (5.5) 6 (10.9) 8 (14.5)
HBV DNA (Log, copies/mL) ‡ 7.9 ± 1.1 5.1 ± 1.21d 4.6 ± 1.3d 3.8 ± 0.9d 3.6 ± 0.8d 3.3 ± 0.7d 2.9 ± 0.5df
T-lymphocyte subpopulations 
(percentage) ‡
CD3+T-lymphocyte 45.1 ± 9.0 45.3 ± 8.9 45.4 ± 8.9 47.4 ± 8.6 48.2 ± 8.7a 50.6 ± 8.4c 54.9 ± 7.9df
CD4+T-lymphocyte 28.1 ± 5.7 28.2 ± 5.5 28.4 ± 5.6 30.6 ± 5.1b 31.7 ± 5.4c 33.6 ± 4.6d 36.5 ± 3.7dg
CD8+T-lymphocyte 40.0 ± 6.7 39.9 ± 7.1 39.8 ± 7.0 36.7 ± 6.6b 35.4 ± 6.2c 32.8 ± 6.2d 28.9 ± 28.9dg
CD4+/CD8+T-lymphocyte ratio 0.7 ± 0.2 0.7 ± 0.2 0.8 ± 0.2 0.9 ± 0.3b 0.9 ± 0.3d 1.1 ± 0.3d 1.3 ± 0.3dh
Biochemichal measurements ‡
Serum ALT level (IU/L) 251.4 ± 66.1 101.6 ± 43.4d 75.7 ± 23.4d 42.6 ± 15.8d 40.5 ± 15.0d 37.0 ± 13.32d 32.9 ± 6.5df
Serum AST level (IU/L) 195.7 ± 81.6 73.9 ± 62.3d 57.6 ± 18.9d 39.5 ± 14.0d 38.2 ± 14.5d 35.7 ± 8.1d 29.9 ± 4.7dh
Serum total bilirubin level (μmol/mL) 26.7 ± 18.1 11.0 ± 4.9d 10.9 ± 4.1d 10.7 ± 3.9d 10.9 ± 4.1d 10.3 ± 3.4d 9.6 ± 3.1d
*ALT, alanine aminotransferase; AST, aspartate aminotransferase; Normal values: ALT, ≤40 IU/L; AST, ≤40 IU/L; total bilirubin ≤17.1 μmol/mL; 
CD3+T, 61.1~77.0; CD4+T, 25.8~41.6; CD8+T, 18.1~29.6; CD4+/CD8+T ratio, 1.57~2.93.
† Date are expressed as no. (%);
‡ Data are expressed as mean ± SD.
ap < 0.05, bp < 0.01, cp < 0.001, dp < 0.0001 vs pre;
fp < 0.01, gp < 0.001, hp < 0.0001 vs 24th.
Table 3: Multivariate multilevel regression model predicting peripheral blood T lymphocyte subpopulations from relevant parameters 
(n = 55)*
CD3+T Lymphocyte CD4+T Lymphocyte CD8+T Lymphocyte
Variables β SE P value β SE P value β SE P value
Fixed effects
Intercept 44.50 1.31 -- 28.09 0.88 -- 39.85 1.09 --
Weeks ** 0.21 0.01 <0.0001 0.18 0.01 <0.0001 -0.23 0.01 <0.0001
Period (4–48 week vs < 4 week) 0.99 0.75 0.19 1.92 0.72 <0.01 -2.07 0.86 0.02
HBV DNA (Log, copies/mL) ** 0.07 0.09 0.47 -0.01 0.09 0.92 0.09 0.11 0.41
HBV DNA (Log, copies/mL) × period -0.29 0.14 0.03 -0.48 0.13 <0.001 0.42 0.16 <0.01
Random effects: Intercept = 8.49 Intercept = 4.71 Intercept = 6.02
SD = 1.73 SD = 1.66 SD = 1.97
*β = Coefficients from the model, SE = Standard Error, SD = Standard Deviation. **Continuous variable.BMC Infectious Diseases 2008, 8:123 http://www.biomedcentral.com/1471-2334/8/123
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these CTLs apparently contribute to the efficacy of lamivu-
dine therapy in patients with hepatitis B. It was reported
by Boni et al [11-13] that an efficient antiviral T cell
response including HBV-specific CD4+ and CD8+ cells can
be restored by lamivudine treatment in CHB patients con-
currently with reduction of viremia, but the restoration of
HBV-specific T-cell reactivity is only transient. In their
study, after an initial increase of frequency of functionally
efficient T cells (first 5 months of therapy), peripheral
blood CD4+ responses declined to pretreatment levels and
this degree of reactivity was maintained after therapy dis-
continuation, throughout the follow-up period. In addi-
tion, this transient restoration of HBV-specific T-cell was
also observed by Mizukoshi et al [31], who suggested that
decreased T cell responsiveness during prolonged therapy
was associated with increased prevalence of lamivudine-
resistant HBV mutants and increased HBV titers. So, pos-
sible reasons for persistant restoration of T-cell function
observed in our study are that entecavir in the treatment
of CHB patients has a stronger antiviral activity specific for
HBV and that resistance to entecavir is lower than that to
lamivudine [19-22].
Our results reveal that T cell failure was significantly asso-
ciated with viral replication level. The stronger independ-
ent predictive effect of time (week) on T cell improvement
might be explained as the effect of treatment course. As a
matter of fact, the restoration of peripheral T cell profile
observed in our study is attributed to the effect of treat-
ment with entecavir, not time (week) itself. However,
entecavir reacts by directly inhibiting HBV DNA replica-
tion, not by modulating the HBV-specific immune
response [19-22]. Indeed, our data showed that the signif-
icant changes of T-cell profile in CHB patients occurred
when viremia viral load level dropped to around 4 log10
copies/mL and thereafter during entecavir-therapy. Fur-
thermore, the decline of viremia viral load was clearly
related with time (week). Therefore, these observations
indicate that the restoration of impaired T cell profile may
be actually directly related with the reduction of viral load
resulting from inhibition of viral replication. Taken
together with recent reports of previous studies [11-13,28-
31], all this accumulating evidence that efficient antiviral
T cell response can be restored by mono-antiviral treat-
ment in CHB patients concurrently with reduction of
viremia demonstrates the importance of viral load in the
pathegenesis of T cell failure in chronic HBV infection.
This study suggests that entecavir can effectively reduce
HBV viral load resulting from inhibition of virus replica-
tion and also maintain a low level for at least 48 weeks. As
a consequence, an increase of CD3+ and CD4+ T cells,
accompanied with a decrease of CD8+ lymphocytes and a
restoration of CD4+/CD8+ ratio to a near normal profile
are evident and also maintained for the whole study
period. As the antiviral action of entecavir is directly on
the virus, with no known direct effect on T cell subpopu-
lations [19-22], our results are most likely explained by a
dose-response causal relationship between viral load and
peripheral T-lymphocyte subpopulations. Thus a high
viral load may be one important factor that contributes to
T cell failure and the latter could be restored by inhibiting
virus replication through efficient antiviral treatment.
The strength of this study lies in the large sample size and
the measurements of T-lymphocyte subpopulations using
modern advanced flow cytometry technology and viral
load with quantitative Real-Time-PCR method. A limita-
tion of this study is that the specific T-lymphocyte sub-
populations and liver-derived T-lymphocytes as well as
their functionality were not explored concurrently.
Another one is that long-term effect of entecavir was not
known from this data set. Although the strong correlation
between viral load and T-lymphocyte subpopulations is
illustrated, further studies are needed to confirm the T cell
responsiveness during prolonged therapy and after with-
drawal of entecavir, and to elucidate the complex interac-
tions among them.
Our results describe a dynamic relationship between T cell
subpopulations and serum viral load that could poten-
tially be used for a better design of HBV treatment in
chronic hepatitis B patients. Inhibition of viral replication
with agents such as novel nucleotide analogues may
enhance the likelihood that therapeutic stimulation of the
antiviral T cell reaponses will induce long-lasting viral
suppression and HBV antigen seroconversion, ultimately
leading to recovery from disease. Further clinical studies
are needed to explore this possibility in persistent HBV-
infected patients.
Conclusion
In this study, profound effects on cellular distribution and
viral replication were found during entecavir-therapy. The
inhibition of virus replication induced by treatment with
entecavir results in a partial restoration and improvement
of the impaired cellular immune response. The restora-
tion was clearly associated with the decreases in serum
viral load, indicating a close correlation between viral
load and T-lymphocyte subpopulations.
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